Research and Markets: Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2012

Thu Feb 7, 2013 9:21am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130207:nBw075915a

DUBLIN--(Business Wire)--

Research and Markets

(http://www.researchandmarkets.com/research/lptmcl/dry_atrophic) has announced
the addition of Global Markets Direct's new report "Dry (Atrophic) Macular
Degeneration - Pipeline Review, H2 2012" to their offering. 

Global Markets Direct's, 'Dry (Atrophic) Macular Degeneration - Pipeline Review,
H2 2012', provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for Dry (Atrophic)
Macular Degeneration, complete with latest updates, and special features on
late-stage and discontinued projects. It also reviews key players involved in
the therapeutic development for Dry (Atrophic) Macular Degeneration.

Scope

- A snapshot of the global therapeutic scenario for Dry (Atrophic) Macular
Degeneration. 

- A review of the Dry (Atrophic) Macular Degeneration products under development
by companies and universities/research institutes based on information derived
from company and industry-specific sources. 

- Coverage of products based on various stages of development ranging from
discovery till registration stages. 

- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics. 

- Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of
route of administration and molecule type. 

- Key discontinued pipeline projects. 

- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under
development for Dry (Atrophic) Macular Degeneration. 

- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage. 

- Plan mergers and acquisitions effectively by identifying players of the most
promising pipeline. 

- Devise corrective measures for pipeline projects by understanding Dry
(Atrophic) Macular Degeneration pipeline depth and focus of Indication
therapeutics. 

- Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope. 

- Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.

For more information visit

http://www.researchandmarkets.com/research/lptmcl/dry_atrophic

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Copyright Business Wire 2013

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.